Genprex, Inc.

NasdaqCM:GNPX Voorraadrapport

Marktkapitalisatie: US$7.7m

Genprex Toekomstige groei

Future criteriumcontroles 0/6

Genprex's earnings are forecast to decline at 12.2% per annum. EPS is expected to grow by 97.2% per annum.

Belangrijke informatie

-12.2%

Groei van de winst

97.2%

Groei van de winst per aandeel

Biotechs winstgroei27.1%
Inkomstengroein/a
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

Low

Laatst bijgewerkt13 Aug 2024

Recente toekomstige groei-updates

Recent updates

Can Genprex (NASDAQ:GNPX) Afford To Invest In Growth?

Aug 16
Can Genprex (NASDAQ:GNPX) Afford To Invest In Growth?

Here's Why We're Watching Genprex's (NASDAQ:GNPX) Cash Burn Situation

Jan 31
Here's Why We're Watching Genprex's (NASDAQ:GNPX) Cash Burn Situation

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Oct 12
Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Genprex stock rises 13% on safety panel nod to continue trial of Reqorsa/Tagrisso combo for lung cancer

Aug 15

We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate

Jun 14
We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate

Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation

Feb 09
Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation

Genprex: Limited Clinical Data To Justify Risk

Nov 19

We Think Genprex (NASDAQ:GNPX) Can Afford To Drive Business Growth

Oct 27
We Think Genprex (NASDAQ:GNPX) Can Afford To Drive Business Growth

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Jun 11
Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Genprex receives IRB approval for NSCLC gene therapy trial; shares up 4%

May 05

Genprex' stock jumps after corporate update

Feb 01

Genprex achieves manufacturing milestone for immunogene therapy for upcoming lung cancer trials

Jan 13

Genprex completes manufacturing scale-up of lung cancer therapy

Dec 22

Winst- en omzetgroeiprognoses

NasdaqCM:GNPX - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/2025N/A-29N/AN/A1
12/31/2024N/A-26N/AN/A1
6/30/2024N/A-26-21-21N/A
3/31/2024N/A-28-23-23N/A
12/31/2023N/A-31-25-25N/A
9/30/2023N/A-31-24-24N/A
6/30/2023N/A-30-24-24N/A
3/31/2023N/A-28-21-20N/A
12/31/2022N/A-24-18-18N/A
9/30/2022N/A-24-17-16N/A
6/30/2022N/A-21-14-14N/A
3/31/2022N/A-19-13-13N/A
12/31/2021N/A-21-14-14N/A
9/30/2021N/A-19-17-15N/A
6/30/2021N/A-18-17-14N/A
3/31/2021N/A-19-17-15N/A
12/31/2020N/A-18-16-14N/A
9/30/2020N/A-15-12-12N/A
6/30/2020N/A-15-12-12N/A
3/31/2020N/A-14-11-10N/A
12/31/2019N/A-11-8-7N/A
9/30/2019N/A-12-8-7N/A
6/30/2019N/A-11-8-7N/A
3/31/2019N/A-14-8-8N/A
12/31/2018N/A-12-7-7N/A
9/30/2018N/A-10-5-5N/A
6/30/2018N/A-8-4-4N/A
3/31/2018N/A-3N/A-2N/A
12/31/2017N/A-3N/A-2N/A
9/30/2017N/A-4N/A-3N/A
6/30/2017N/A-4N/A-2N/A
3/31/2017N/A-5N/A-2N/A
12/31/2016N/A-4N/A-1N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: GNPX is forecast to remain unprofitable over the next 3 years.

Winst versus markt: GNPX is forecast to remain unprofitable over the next 3 years.

Hoge groeiwinsten: GNPX is forecast to remain unprofitable over the next 3 years.

Omzet versus markt: Insufficient data to determine if GNPX's revenue is forecast to grow faster than the US market.

Hoge groei-inkomsten: GNPX is forecast to have no revenue next year.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if GNPX's Return on Equity is forecast to be high in 3 years time


Ontdek groeibedrijven